Company Profile - Swedish Orphan Biovitrum AB
Introduction
Swedish Orphan Biovitrum AB (Sobi) is an integrated biopharmaceutical company. It focuses on the development of products for the treatment of a few rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on hemophilia, immunology, specialty care, inflammation, and genetic and metabolic diseases. The company also provides innovative treatment for conditions such as amyotrophic lateral sclerosis (ALS). Sobi also manufactures and markets specialty products for rare diseases for partner companies. The company has operational presence in Europe, the Middle East, North America, Russia, and Asia. Sobi is headquartered in Stockholm, Sweden.
Company info
Country (HQ): | Sweden |
Sector: | Pharmaceuticals and Healthcare |
Market Cap (US$ m): | 7,089 |
Revenue (US$ m): | 1,858 (2022) |
Innovation ranking
Innovation score
Closest peers in the Pharmaceuticals and Healthcare sector
Innovation Ranking
Johnson & Johnson
United States
Pharmaceuticals and Healthcare
F. Hoffmann-La Roche Ltd
Switzerland
Pharmaceuticals and Healthcare
Swedish Orphan Biovitrum AB
Sweden
Pharmaceuticals and Healthcare
EyeGate Pharmaceuticals Inc
United States
Pharmaceuticals and Healthcare
Shin Poong Pharm Co Ltd
South Korea
Pharmaceuticals and Healthcare
Are you ranked? Get the Innovation Ranking Report
-
Company Ranking Report
- If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
- Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
- Contextualised information on the company's standing in relation to peers
- Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
- Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
- Rosettes
- Certificate of Achievement
- Press release